The £144M NHS Fabry market already has two established agents, so only an ADA-positive or female-heterozygote niche clears NICE.

Agalsidase beta (Fabrazyme, Sanofi) is NHS-commissioned via clinical policy outside the formal NICE technology appraisal process, while migalastat (Galafold, Amicus) is commissioned via NICE's Highly Specialised Technology route, HST4. Together they cover the great majority of the UK's 700-900 NHS Fabry patients at an estimated £144 million a year, the largest single Fabry market in Europe. Migalastat is available only for amenable mutations, confirmed via HEK-assay testing at four NHS metabolic labs: Royal Free London, Addenbrooke's Cambridge, Manchester, and Sheffield. Pegunigalsidase alfa (Elfabrio, Chiesi), MHRA-approved in August 2023, received a positive NICE recommendation, TA915, for the antibody-positive inadequate-responder subgroup, defining the access framework any new agent must match.

Two unmet-need pockets exist within an otherwise well-covered market. An estimated 50-80 UK patients on agalsidase beta develop high-titre antibodies and experience faster eGFR decline, 3-4 mL per minute a year versus 1.5-2 in ADA-negative patients, plus continued cardiac hypertrophy progression despite ERT. Separately, 300-400 of the 700-900 UK NHS Fabry patients are female, and an estimated 80-120 symptomatic women remain undertreated because their presentation is classified as asymptomatic. Royal Free London's National Fabry Service is NICE's appointed clinical expert for every UK Fabry appraisal, and a formal scientific collaboration there, typically £150,000-350,000 over two to three years, is the highest-return pre-launch investment available for either niche.

Niche selection, not general positioning, is what clears NICE's budget scrutiny.

Five questions this report answers:

Q1 - With £144M/year NHS spend already covered, what unmet-need niche gives a new agent a viable NICE case?

Q2 - How large are the UK ADA-positive and undertreated female-heterozygote Fabry populations?

Q3 - What Royal Free London partnership and NICE submission sequence does a UK Fabry launch need?

Q4 - What does a pre-launch Fabry asset need to prove to succeed in the UK market?

Q5 - What deliverables and verification standard does every AXLRx UK Fabry assessment include?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#FabryDisease #UK #NICE #NHS #LaunchReadiness #RareDisease

Live report page:  https://axlrx.ai/fabry-disease/uk/launch-readiness/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-                                     hello@axlrx.ai

Web-                                     https://axlrx.ai/